
Kaifeng Jin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10017103/publications.pdf Version: 2024-02-01



KAIEENC IIN

#	Article	IF	CITATIONS
1	Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients. Annals of Surgery, 2022, 275, e626-e635.	4.2	95
2	Intratumoral CXCL13 ⁺ CD8 ⁺ T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. , 2021, 9, e001823.		87
3	CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunology, Immunotherapy, 2021, 70, 1831-1840.	4.2	32
4	Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. , 2022, 10, e003416.		28
5	Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1497-1506.	4.2	20
6	Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. Oncolmmunology, 2021, 10, 1915560.	4.6	17
7	CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. British Journal of Cancer, 2022, 126, 1581-1588.	6.4	16
8	<scp>Lymphocyteâ€activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epsteinâ€Barr virusâ€positive and MLH1â€defective gastric cancer patients</scp> . International Journal of Cancer, 2021, 148, 759-768.	5.1	15
9	Intratumoral CD103 ⁺ CD4 ⁺ T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients. Oncolmmunology, 2020, 9, 1844402.	4.6	14
10	Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response. OncoImmunology, 2020, 9, 1856468.	4.6	8
11	Tumor-infiltrating podoplanin ⁺ cells in gastric cancer: clinical outcomes and association with immune contexture. Oncolmmunology, 2020, 9, 1845038.	4.6	7
12	TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. British Journal of Cancer, 2022, 126, 1310-1317.	6.4	7
13	Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 166.e15-166.e25.	1.6	6
14	NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. , 2022, 10, e004569.		5
15	Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. Annals of Surgical Oncology, 2022, , 1.	1.5	4
16	Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 109.e11-109.e20.	1.6	3
17	Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	2
18	Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 2117-2126.	4.2	1

		15	0	
#	Article	IF	CITATIONS	
19	ASO Visual Abstract: Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. Annals of Surgical Oncology, 2022, 29, 2504-2504.	1.5	Ο	